HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure (NCT02608632) | Clinical Trial Compass
UnknownPhase 2
HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure
Russia170 participantsStarted 2013-02
Plain-language summary
To increase the number of responders using HFS-guided renal artery denervation (RDN) in patients with resistant and moderate resistant hypertension
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Office-based systolic blood pressure of ≥140/90 mm Hg and \<160/100 mm Hg (moderate resistant hypertension) or ≥160/100 mm Hg (severe resistant hypertension), despite treatment with 3 antihypertensive drugs (including a diuretic).
* A glomerular filtration rate ≥45 mL/min/1⋅73 m2, with modification of diet using a renal disease formula.
Exclusion Criteria:
* Secondary causes of hypertension
* Severe renal artery stenosis or dual renal arteries
* Congestive heart failure
* Left ventricular ejection fraction \<35%
* Previous renal artery stenting or angioplasty
* Type 1 diabetes mellitus
What they're measuring
1
number of responders to renal denervation procedure
Timeframe: 12 month
Trial details
NCT IDNCT02608632
SponsorMeshalkin Research Institute of Pathology of Circulation